I am a medical epidemiologist (MD in 1988 at Paris V, specialisation in rheumatology in 1990, Paris V, and DrPH from Harvard School of Public Health in 1993) specialized in infectious diseases epidemiology. After working at WHO at the clinical research unit of the Global Program on AIDS (1993-1994), I spent five years in Ethiopia and two years in the Netherlands working as the Program Manager of the Ethio-Netherlands AIDS Research Project (1994-2001). In 2002, I joined Institut Pasteur to launch the Emerging Diseases Epidemiology unit. There, my focus has been on viral hepatitis C (North-Coordinator of the ANRS research site on viral hepatitis; www.hepnile.org) and emerging infections such as the SARS (Scientific Coordinator of the EPISARS project which aimed prevent the re-emergence of SARS through the control of its animal reservoir) and the MERS-CoV. I also have a strong teaching involvement, as co-Director and founder of the Pasteur-Cnam School of Public Health (http://ecole-pasteur.cnam.fr), and coordinator of a master in public health with strong focus on infectious diseases. In 2014, I was appointed as Director of the newly created Pasteur Centre for Global Health Research and Education.
Cliquez pour voir le graph
Connexions
Cliquez pour voir la ligne de temps
Ligne de temps
Projets Transversaux
Projets
Publications
Télécharger-
2022Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22., Euro Surveill 2022 01; 27(1): .
-
2021Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France., Lancet Reg Health Eur 2021 Nov; (): 100278.
-
2021SARS-CoV-2 transmission across age groups in France and implications for control., Nat Commun 2021 11; 12(1): 6895.
-
2021Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection., J Infect Dis 2021 11; 224(9): 1489-1499.
-
2021Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France., Lancet Reg Health Eur 2021 Sep; 8(): 100171.
-
2021Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection., EBioMedicine 2021 Aug; 71(): 103561.
-
2021Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study., Lancet Reg Health Eur 2021 Aug; 7(): 100148.
-
2021A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures., EClinicalMedicine 2021 Aug; 38(): 101001.
-
2021Education and mental health: good reasons to vaccinate children., Lancet 2021 07; 398(10298): 387.
-
2021Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France., EBioMedicine 2021 Aug; 70(): 103495.
-
+Voir la liste complète de publications